Telehealth platform Hims & Hers Health (HIMS) is scheduled to announce its third-quarter earnings on Monday, November 3, and the options market is expecting a volatile reaction. According to TipRanks’ Options Tool, traders are expecting a 14.56% move in either direction in reaction to Q3 results, which is modestly higher than HIMS stock’s average post-earnings move (in absolute terms) of 13.35% over the past four quarters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The implied move suggests that investors are bracing for sharp swings as they seek updates on momentum in Hims & Hers Health’s core business and expansion strategy.
What Is Wall Street Expecting from HIMS’ Q3 Earnings?
Wall Street expects Hims & Hers Health to report Q3 earnings per share (EPS) of $0.09, compared to $0.32 in the prior-year quarter. Revenue is estimated to grow 44.5% year over year to $580.24 million.
Despite declining 20.3% over the past month due to insider selling and other reasons, HIMS stock is still up about 87% year-to-date. While the company is expanding into international markets and lucrative areas such as testosterone and menopause support, Wall Street is currently cautious about HIMS stock due to concerns about intense competition and legal and regulatory risks.
Ahead of the Q3 results, the company announced its plans to roll out new GLP-1 “microdosing treatments.”
Analysts’ Views Ahead of Hims & Hers Health’s Q3 Earnings
Ahead of the Q3 results, TD Cowen analyst Jonna Kim reiterated a Hold rating on Hims & Hers Health stock with a price target of $48. Kim explained that she remains sidelined on HIMS stock, as data show decelerating growth and tougher comparisons ahead. The analyst believes that compounded GLP-1 demand remains solid, though slowing compared to the first half of 2025. However, the core hims.com business is moderating. Kim expects the company to report Q3 EPS in line with the Street’s estimate, with full-year guidance reiterated.
Meanwhile, KeyBanc analyst Justin Patterson recently initiated coverage on Hims & Hers stock with a Hold rating. Patterson noted that Hims & Hers is a disruptive direct-to-consumer (DTC) healthcare business with 2.4 million subscribers. The analyst expects HIMS’ revenue to rise from $2.35 billion in 2025 to $3.34 billion in 2027, with EBITDA (earnings before interest, taxes, depreciation, and amortization) growing from $309 million to $505 million over the same period. He expects the company to optimize subscriber and revenue growth in the year ahead, “while allowing for gradual EBITDA margin expansion.”
Overall, Patterson is sidelined on HIMS stock as he sees potential constraints on margin expansion in 2026, despite growth opportunities from international expansion and new treatment launches. The analyst noted certain risks, like intense competition, regulatory scrutiny, tough comparisons through Q1 2026 due to previous GLP-1 shortages, and limited experience in international markets.
AI Analyst Is Cautious on HIMS Stock Ahead of Q3 Print
Interestingly, TipRanks’ AI Analyst has assigned a Neutral rating to HIMS stock with a price target of $47, indicating about 3.02% upside potential. TipRanks’ AI analyst’s rating is based on solid financial performance and positive earnings call insights, indicating growth potential. However, technical analysis suggests bearish momentum. Moreover, HIMS stock’s high P/E ratio raises valuation concerns. The company’s high leverage and cash flow issues also pose risks.
Is HIMS Stock a Good Buy?
Currently, Wall Street has a Hold consensus rating on Hims & Hers stock based on eight Holds, two Buys, and two Sells recommendations. The average HIMS stock price target of $49.75 indicates a 9.7% upside potential from current levels.
